Anti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationPaolo A Ascierto
Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 9:196. 2011
....
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Paolo A Ascierto
Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
J Transl Med 11:54. 2013
..The challenge will be to identify the individual immunoprofile of each patient and the consequent choice of optimal therapy or combination of therapies to be used...
- Do BRAF inhibitors select for populations with different disease progression kinetics?
Paolo Antonio Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Department of Melanoma, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
J Transl Med 11:61. 2013
....
- Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
Antonio Daponte
Department of Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Via Mariano Semmola, 80131, Naples, Italy
J Transl Med 11:38. 2013
..The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 factorial design trial...
- Tumor biobanks in translational medicine
Gerardo Botti
Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
J Transl Med 10:204. 2012
....
Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert reviewPaolo A Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale, Naples, Italy
Crit Rev Oncol Hematol 85:149-61. 2013
....
- Lean oncology: a new model for oncologists
Vincenzo Montesarchio
Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131, Naples, Italy
J Transl Med 10:74. 2012
..Its main objective is the centrality of the patient...
- Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report
Ester Simeone
Istituto Nazionale Tumori, Fondazione G, Pascale, Napoli, Italy
J Med Case Rep 6:131. 2012
..abstract:..
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Paolo A Ascierto
Melanoma, Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
J Transl Med 10:107. 2012
..The aim of this analysis was to identify factors that could potentially be used to optimise the order in which ipilimumab and BRAF inhibitors are administered in this patient population...
- Defining the critical hurdles in cancer immunotherapy
Bernard A Fox
Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
J Transl Med 9:214. 2011
..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
- The immune score as a new possible approach for the classification of cancer
Jerome Galon
INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
J Transl Med 10:1. 2012
....
- The role of BRAF V600 mutation in melanoma
Paolo A Ascierto
Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
J Transl Med 10:85. 2012
....
- Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 10:83. 2012
....
- NF-κB as potential target in the treatment of melanoma
Gabriele Madonna
Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione, G, Pascale, Napoli, Italy
J Transl Med 10:53. 2012
..Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies...
- Main roads to melanoma
Giuseppe Palmieri
Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche CNR, Sassari, Italy
J Transl Med 7:86. 2009
..Progression from normal melanocytes to malignant metastatic cells in melanoma patients is the result of a combination of down- or up-regulation of various effectors acting on different molecular pathways...
- Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
Maria Libera Ascierto
Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA
BMC Cancer 11:451. 2011
....
- Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies
Paolo A Ascierto
Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
Semin Oncol 37:508-16. 2010
..As new class of drugs in cancer therapy, immunostimulatory mAbs have resulted in redefinition of tumor response criteria and rethinking of the rationale for combining these among each other and with other strategies...
- Melanoma: a model for testing new agents in combination therapies
Paolo A Ascierto
Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy
J Transl Med 8:38. 2010
....
- The role of spectrophotometry in the diagnosis of melanoma
Paolo A Ascierto
National Cancer Institute, Naples, Italy
BMC Dermatol 10:5. 2010
..Spectrophotometry (SPT) could represent a promising technique for the diagnosis of cutaneous melanoma (CM) at earlier stages of the disease. Starting from our experience, we further assessed the role of SPT in CM early detection...
- Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment
Paolo A Ascierto
Unit of Medical Oncology and Innovative Therapy and Melanoma Cooperative Group, National Tumor Institute, Naples, Italy
J Transl Med 8:76. 2010
....
- Combination therapy: the next opportunity and challenge of medicine
Paolo A Ascierto
Medical Oncology and Innovative Therapies Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G, Pascale, Napoli, Italy
J Transl Med 9:115. 2011
..After recent successes in the immunotherapy field (Sepuleucel-T, ipilimumab) and the new promising small molecule therapies, cancer should be the next challenge for combination strategies...
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 9:32. 2011
..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
Update on PEG-interferon α-2b as adjuvant therapy in melanomaRossella Di Trolio
Unit of Medical Oncology and Innovative Therapy, G Pascale Institute of National Tumor Foundation, Naples, Italy
Anticancer Res 32:3901-9. 2012
..This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease...
- CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type
Stefania Scala
Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131, Naples, Italy
Cancer Immunol Immunother 56:1589-95. 2007
..CXCR4, a chemokine receptor, is a prognostic factor in cutaneous melanoma involved in angiogenesis and metastasis formation. The aim of this study was to evaluate the expression of CXCR4 in uveal melanoma...
- Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies
Paolo A Ascierto
Pascale NAtional Cancer Institute, Naples, Italy
J Clin Oncol 23:7660-8. 2005
..Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted...
- Increased HOX C13 expression in metastatic melanoma progression
Monica Cantile
Pathology Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131, Naples, Italy
J Transl Med 10:91. 2012
..Among these, Hox C13 is also involved in the expression control of the human keratin genes hHa5 and hHa2, and recently it was identified as a member of human DNA replication complexes...
- Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
Nicola Mozzillo
Department of Surgery, National Cancer Institute, Via Mariano Semmola, Naples, Italy
J Transl Med 10:131. 2012
..ECT has been used in palliative management of metastatic melanoma to improve patients' quality of life. This is, to our knowledge, the first application of ECT as neoadjuvant treatment of metastatic subcutaneous melanoma...
- Human melanoma metastases express functional CXCR4
Stefania Scala
Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Naples, Italy
Clin Cancer Res 12:2427-33. 2006
..The chemokine receptor CXCR4 was identified as an independent predictor of poor prognosis in primary melanoma. The aim of the study was to investigate the role of CXCR4 in human melanoma metastases...
- Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
Giusy Gentilcore
Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
BMC Cancer 13:17. 2013
..We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations...
- Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1
Ester Simeone
Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
J Immunotoxicol 9:241-7. 2012
..that represent the natural evolution of future melanoma therapy...
- Adjuvant therapy of melanoma with interferon: lessons of the past decade
Paolo A Ascierto
Unit of Medical Oncology and Innovative Therapy, Melanoma Cooperative Group, National Tumor Institute, Naples, Italy
J Transl Med 6:62. 2008
..Future efforts may well build toward patient-oriented therapy based upon the knowledge of the unique molecular features of this disease and the immune system of each melanoma patient...
- Adjuvant treatment of malignant melanoma: where are we?
Paolo A Ascierto
Unit of Clinical Immunology, Melanoma Cooperative Group, National Cancer Institute, Via Mariano Semmola, 80131 Naples, Italy
Crit Rev Oncol Hematol 57:45-52. 2006
..Conversely, considering the improvement of OS as the main target of MM adjuvant therapy, the "wait and watch" attitude remains the only approach to be pursued at present. It is a physician's choice...
- Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination
Ignacio Melero
Department of Oncology, Centro de Investigación Médica Aplicada, Clinica Universidad de Navarra, Pamplona, Spain
Clin Cancer Res 19:997-1008. 2013
..Combinations with other more conventional means of treatment such as radiotherapy, chemotherapy, or cancer vaccines also hold much promise...
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A Ascierto
National Tumor Institute, Foundation G Pascale, Naples, Italy
Lancet Oncol 14:249-56. 2013
..We aimed to assess the use of MEK162, a small-molecule MEK1/2 inhibitor, in patients with NRAS-mutated or Val600 BRAF-mutated advanced melanoma...
